183 related articles for article (PubMed ID: 25050704)
1. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
2. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
3. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
5. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
6. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
7. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
8. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
[TBL] [Abstract][Full Text] [Related]
9. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
Dons EM; Raimondi G; Zhang H; Zahorchak AF; Bhama JK; Lu L; Ezzelarab M; Ijzermans JN; Cooper DK; Thomson AW
Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
[TBL] [Abstract][Full Text] [Related]
12. CD52 is a molecular target in advanced systemic mastocytosis.
Hoermann G; Blatt K; Greiner G; Putz EM; Berger A; Herrmann H; Cerny-Reiterer S; Gleixner KV; Walz C; Hoetzenecker K; Müllauer L; Reiter A; Sotlar K; Sexl V; Valent P; Mayerhofer M
FASEB J; 2014 Aug; 28(8):3540-51. PubMed ID: 24760752
[TBL] [Abstract][Full Text] [Related]
13. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
14. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
15. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor VC; Sims M; Brett S; Field MC
Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S
Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892
[TBL] [Abstract][Full Text] [Related]
17. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
Kanda J; Lopez RD; Rizzieri DA
Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
Reiff A; Shaham B; Weinberg KI; Crooks GM; Parkman R
J Clin Immunol; 2011 Aug; 31(4):615-22. PubMed ID: 21541793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]